WEST LAFAYETTE, Ind., May 13, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data featuring Endocyte's SMDC, EC1456 will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2015, in Chicago.
The EC1456 poster shows that EC1456 is generally well tolerated in previously treated cancer patients, with no treatment-related deaths, SAE's, dose modifications, or Grade 4 toxicities on either schedule. There is also no evidence of cumulative or late emerging toxicity, thus far. Grade 1-2 toxicities include nausea, vomiting, stomatitis, abdominal pain, constipation, diarrhea, paresthesia, and fatigue. Cohort expansions are continuing at 4.5 mg/m2 (weekly schedule) and 2.5 mg/m2 (biweekly schedule). Anti-tumor activity with EC1456 is suggested by prolonged stable disease in FR+ patients: 11/20 patients had stable disease as their best study response. EC1456 shows a dose-dependent PK profile that has prolonged drug concentration above IC50 and is more favorable than the 1st generation SMDC, vintafolide.
The poster will be available on Endocyte's website following presentation at the conference.
|Presentation is as follows:|
|Title:||Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancer (CA)|
|Presenter:||Daniela Matei, M.D., Indiana University Simon Cancer Center|
|When:||Saturday, May 30, 8 a.m. – 11:30 a.m. EDT|
|Session Title:||Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics|
|Location:||S Hall A|
The abstract for EC1169, titled "Phase 1 study of the PSMA-tubulysin small molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC)" will be published in the ASCO 2015 Abstract Book. The abstract will provide an update on the safety and efficacy observed in the ongoing phase 1 dose escalation trial.
EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).
EC1169 is an investigational proprietary, injectable, SMDC consisting of a PSMA targeting ligand (DUPA analog) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1169 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. EC1169 is currently being evaluated in a Phase 1 study in patients with recurrent metastatic, castration-resistant prostate cancer (MCRPC) (ClinicalTrials.gov Identifier: NCT02202447).
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, email@example.com